Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Zydus Lifesciences Limited Press Release Jan 12 2023

· Issued by Zydus Lifesciences Limited via NSE India

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Brexpiprazole Tablets, along with a period of shared exclusivity. The approval allows Zydus to market the drug in various dosages, which is indicated for treating major depressive disorder and schizophrenia. This approval marks a significant milestone as Zydus was among the first applicants to submit a complete application for this medication. The drug will be manufactured at Zydus's facility in Ahmedabad, India, and had substantial annual sales in the US market according to recent data.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 12, 2023, titled "Zydus receivesfinal approval and 180 days shared exclusivity from the USFDA for Brexpiprazole Tablets".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases